FDA issues Emergency Use Authorization for baricitinib + remdesivir in hospitalized patients with COVID-19.- Eli Lilly

Invivyd, Inc. a biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, announced that Pemgarda (pemivibart), formerly VYD 222, a half-life extended monoclonal antibody (mAb), has received emergency use authorization (EUA) from the FDA for the pre-exposure prophylaxis (prevention) of COVID-19 in adults and adolescents (12 years of age and older weighing at least 40 kg) who have moderate-to-severe immune compromise due to certain medical conditions or receipt of certain immunosuppressive medications or treatments and are unlikely to mount an adequate immune response to COVID-19 vaccination.